기계환기관련 폐렴치료 시 Aerosolized Colistin의 효과 및 안전성에 대한 체계적 문헌 고찰 및 메타분석
Efficacy and Safety of Aerosolized Colistin in the Treatment of Ventilator-Associated Pneumonia: A Systematic Review and Meta-analysis
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: It is recommended to use aerosolized (AS) colistin in patients undergoing mechanical ventilation therapy as anadjunctive in the latest guidelines, in spite of high nephrotoxicity and limited studies. In this study, systematic reviews and metaanalyzeswere conducted to evaluate the safety and efficacy of AS colistin in patients with ventilator-associated pneumoniaMethods: Two authors independently searched related literature published from Pubmed and EMBASE until July 2016 and includeda study comparing adjunctive AS colistin with intravenous (IV) colistin monotherapy. The primary outcome was the clinical responserate, the secondary outcome was the overall mortality, and nephrotoxicity. The publication bias was evaluated using the Egger'stest. Results: Of the total 279 articles, nine were finally included in the final analysis. There was a significant difference between theadjunctive AS colistin group and the IV colistin monotherapy group for the treatment-response rate (odds ratio (OR), 1.56; 95% CI,1.14-2.14; p = 0.005; I2 = 36%), although there was no significant difference in overall mortality (OR, 0.77; 95% CI, 0.57-1.04; p =0.09; I2 = 20%). However, there was no significant difference between the two groups in nephrotoxicity (OR, 1.13; 95% CI, 0.74-1.74;p = 0.57; I2 = 4%). Conclusion: The addition of aerosolized colistin to IV colistin monotherapy showed better results in terms ofefficacy than IV colistin monotherapy and did not show any significant difference in terms of total mortality and nephrotoxicity. Additional large-scale studies of this need to be verified.
Abstract
Background: It is recommended to use aerosolized (AS) colistin in patients undergoing mechanical ventilation therapy as anadjunctive in the latest guidelines, in spite of high nephrotoxicity and limited studies. In this study, systematic reviews and metaanalyzeswere conducted to evaluate the safety and efficacy of AS colistin in patients with ventilator-associated pneumoniaMethods: Two authors independently searched related literature published from Pubmed and EMBASE until July 2016 and includeda study comparing adjunctive AS colistin with intravenous (IV) colistin monotherapy. The primary outcome was the clinical responserate, the secondary outcome was the overall mortality, and nephrotoxicity. The publication bias was evaluated using the Egger'stest. Results: Of the total 279 articles, nine were finally included in the final analysis. There was a significant difference between theadjunctive AS colistin group and the IV colistin monotherapy group for the treatment-response rate (odds ratio (OR), 1.56; 95% CI,1.14-2.14; p = 0.005; I2 = 36%), although there was no significant difference in overall mortality (OR, 0.77; 95% CI, 0.57-1.04; p =0.09; I2 = 20%). However, there was no significant difference between the two groups in nephrotoxicity (OR, 1.13; 95% CI, 0.74-1.74;p = 0.57; I2 = 4%). Conclusion: The addition of aerosolized colistin to IV colistin monotherapy showed better results in terms ofefficacy than IV colistin monotherapy and did not show any significant difference in terms of total mortality and nephrotoxicity. Additional large-scale studies of this need to be verified.
참고문헌 (32)
- Vincent JL, "The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee", JAMA, 274(8), pp.639~644 (1995)
- Rello J, "Epidemiology and outcomes of ventilator-associated pneumonia in a large US database", CHEST, 122(6), pp.2115~2121 (2002)
- Kollef KE, "Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria", CHEST, 134(2), pp.281~287 (2008)
- Melsen WG, "Attributable mortality of ventilator-associated pneumonia : a meta-analysis of individual patient data from randomised prevention studies", Lancet Infect Dis, 13(8), pp.665~671 (2013)
- Siempos, II, "Predictors of mortality in adult patients with ventilator-associated pneumonia: a metaanalysis", Shock (Augusta, Ga), 33(6), pp.590~601 (2010)
- Sievert DM, "Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010", Infect Control Hosp Epidemiol, 34(1), pp.1~14 (2013)
- Jones RN, "Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia", Clin Infect Dis: an official publication of the Infectious Diseases Society of America, 51(Suppl 1), pp.S81~S87 (2010)
- Ling LL, "A new antibiotic kills pathogens without detectable resistance", Nature, 517(7535), pp.455~459 (2015)
- Chemical Sciences R, "The National Academies Collection: Reports funded by National Institutes of Health", Technological Challenges in Antibiotic Discovery and Development: A Workshop Summary (2014), National Academies Press (US)Copyright 2014 by the National Academy of Sciences
- Livermore DM, "Has the era of untreatable infections arrived?", J Antimicrob Chemother, 64(suppl 1), pp.i29~i36 (2009)
- Imberti R, "Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration", CHEST, 138(6), pp.1333~1339 (2010)
- Ratjen F, "Pharmacokinetics of inhaled colistin in patients with cystic fibrosis", J Antimicrob Chemother, 7(2), pp.306~311 (2006)
- Palmer LB, "Aerosolized antibiotics in mechanically ventilated patients : delivery and response", Crit Care Med, 26(1), pp.31~39 (1998)
- Kalil AC, "Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society", Clin Infect Dis: an official publication of the Infectious Diseases Society of America, 63(5), pp.e61~e111 (2016)
- Valachis A, "The role of aerosolized colistin in the treatment of ventilator-associated pneumonia : a systematic review and metaanalysis", Crit Care Med, 43(3), pp.527~533 (2015)
- Wells G, "The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses", ~
- "The Cochrane Collaboration", 2015
- Li J, "Colistin : the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections", Lancet Infect Dis, 6(9), pp.589~601 (2006)
- Nation RL, "Colistin in the 21st century", Current opinion in infectious diseases, 22(6), pp.535~543 (2009)
- Higgins JP, "Measuring inconsistency in meta-analyses", BMJ(Clinical research ed), 327(7414), pp.557~560 (2003)
- Egger M, "Bias in meta-analysis detected by a simple, graphical test", BMJ (Clinical research ed), 315(7109), pp.629~634 (1997)
- Doshi NM, "Adjunctive aerosolized colistin for multi-drug resistant gram-negative pneumonia in the critically ill : a retrospective study", BMC anesthesiology, 13(1), pp.45~ (2013)
- Kalin G, "Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment?", J Infect Chemother: official journal of the Japan Society of Chemotherapy, 18(6), pp.872~877 (2012)
- Kofteridis DP, "Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study", Clin Infect Dis: an official publication of the Infectious Diseases Society of America, 51(11), pp.1238~1244 (2010)
- Korbila IP, "Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study", Clin Microbiol Infect: the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 16(8), pp.1230~1236 (2010)
- Naesens R, "A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa", BMC infectious diseases, 11, pp.317~ (2011)
- Rattanaumpawan P, "Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria", J Antimicrob Chemother, 65(12), pp.2645~2649 (2010)
- Tumbarello M, "Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistinonly susceptible gram-negative bacteria", CHEST, 144(6), pp.1768~1775 (2013)
- Polat M, "Treatment of Ventilator-Associated Pneumonia Using Intravenous Colistin Alone or in Combination with Inhaled Colistin in Critically Ill Children", Paediatr Drugs, 17(4), pp.323~330 (2015)
- Demirdal T, "Is inhaled colistin beneficial in ventilator associated pneumonia or nosocomial pneumonia caused by Acinetobacter baumannii?", Ann Clin Microbiol Antimicrob, 15, pp.11~ (2016)
- "Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia", Am J Respir Crit Care Med, 171(4), pp.388~416 (2005)
- Pérez-Pedrero M, "Nebulized colistin treatment of multi-resistant Acinetobacter baumannii pulmonary infection in critical ill patients", Med Intensiva(English Edition), 35(4), pp.226~231 (2011)